IP Library Granted Patent US 8,293,708
Granted Patent B2
US 8,293,708 · App. 12/063,278 · Granted Oct 23, 2012

Liquid formulations N-terminal serine of pegylated growth hormone

Assignee: Novo Nordisk Health Care A/G
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,293,708
App. No.
12/063,278
Granted
Oct 23, 2012
Kind
B2
Abstract

Pharmaceutical compositions comprising pegylated growth hormone at pH 7 or below are provided.

Claims (72)

1. A pharmaceutical composition comprising a pegylated growth hormone and at least one pharmaceutically acceptable excipient, wherein said pegylated growth hormone comprises a growth hormone and a PEG, wherein said growth hormone and said PEG is connected via an oxime bond, and optionally via a linker, wherein said composition does not comprise any substantial amount of carbonate and said composition has a pH from 5 to 7, wherein the PEG moiety is attached to the growth hormone at a serine in the N-terminal of said growth hormone and wherein the composition comprises:

Histidine:

0.002 to 0.34 mg per mg of

pegylated growth hormone

Poloxamer 188:

1 to 4

mg/ml

Mannitol:

10 to 30

mg/ml

Phenol:

1 to 5

mg/ml

pegylated growth hormone:

1 to 200

mg/ml

pH:

5-7.

2. The composition according to claim 1 comprising

Histidine:

0.0085 mg per mg of

pegylated growth hormone

Poloxamer 188:

1.5

mg/ml

Mannitol:

20

mg/ml

Phenol:

5

mg/ml

pegylated growth hormone:

1 to 200

mg/ml

pH:

6.1.

3. A pharmaceutical composition comprising a pegylated growth hormone and at least one pharmaceutically acceptable excipient, wherein said pegylated growth hormone comprises a growth hormone and a PEG, wherein said growth hormone and said PEG is connected via an oxime bond, and optionally via a linker, wherein said composition does not comprise any substantial amount of carbonate and said composition has a pH from 5 to 7, wherein the PEG moiety is attached to the growth hormone at a serine in the N-terminal of said growth hormone and wherein the composition comprises:

Glycin:

2 to 7

mg/ml

Mannitol:

10 to 30

mg/ml

Total PO 4 3− :

2 to 20

mM

Phenol:

1 to 5

mg/ml

pegylated growth hormone:

1 to 200

mg/ml

pH:

5-7

4. The composition according to claim 3 comprising

Glycin:

2.2

mg/ml

Mannitol:

11

mg/ml

Total PO 4 3− :

4.5

mM

Phenol:

5

mg/ml

pegylated growth hormone:

1 to 200

mg/ml

pH:

5-7

Assignments (2)
CHANGE OF ADDRESS Recorded Jun 19, 2013
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 030653/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2009
From: RESLOW, MATS
To: NOVO NORDISK HEALTH CARE AG
Reel/Frame 022180/0048 →
Priority Claims (1)
EP 05107917 · Aug 30, 2005 · regional
Continuity (1)
Related Publication 20090325865A1 · Dec 31, 2009